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Cyclosporine associated lesions in native kidneys of diabetic pancreas
transplant recipients. Five years of normoglycemia following pancreas
transplantation (PT) does not ameliorate glomerular lesions in patients
with their own kidneys and with long-term insulin-dependent diabetes
(IDDM) (Lancet 342:1193, 1993). All these patients received cyclosporine(CsA) as part of their immunosuppression. Here we examined the
relationship of CsA dose and blood levels to the presence and severity of
CsA-associated renal lesions and changes in renal function in these PT
patients. Renal biopsies were taken before (0) and two and five years after
PT from 13 non-uremic LDDM patients and were compared with baseline
and five year biopsies from 10 IDDM controls (C). CsA dose was reduced
from 10 3 mg/lg/day in the first month to 5 2 in the fifth year post-PT.
Creatinine clearance (Car) decreased by 34% at one year post-PT and was
stable thereafter, and did not change in C. The decline in from 0 to
one year was related to CsA blood levels and dose (P < 0.005) at one year.
Cortical interstitial volume fraction [Vv(Int/Cortex)], the index of tubular
atrophy, and % sclerotic glomeruli increased significantly from 0 to five
years post-PT (P < 0.005, 0.01 and 0.001, respectively), but did not change
in C. There was no significant change from 0 to two years post-PT in these
lesions, while there was a clear progression from two to five years. Mean
CsA dose and blood levels in the first year post-PT correlated with the
increase (A) in Vv(Int/Cortex) at five years (P < 0.05 for both). The best
predictor of A Vv(Int/Cortex) was the change in Ccr over the first year
post-PT (P < 0.003). In conclusion, in five years serious tubulointerstitial
and glomerulosclerotic lesions developed in PT recipients on CsA therapy,
but not in IDDM C. These lesions were best predicted by the decline in
Ccr and CsA blood levels and dose during the first year post-PT. Despite
early CsA dose reductions, and stabilization of Car, structural lesions
progressed from two to five years post-PT.
Pancreas transplantation (PT) is being performed with increas-
ing frequency as a cure for insulin-dependent diabetes (IDDM)
[1]. We have recently reported that five years of normoglycemia
following successful PT is unable to reverse established diabetic
glomerular lesions in IDDM patients with their own kidneys [21.
However, the structural abnormalities in the diabetic kidney
involve not only glomeruli, but also arterioles, tubules and inter-
stitium [3]. PT recipients currently routinely receive cyclosporine
(CsA) as part of their immunosuppressive regimens. This drug is
known to have detrimental effects on renal structure including
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vascular lesions of arteriolar hyalinosis and CsA arteriolopathy, as
well as tubular atrophy and striped interstitial fibrosis [4—7]. Most
studies on the renal morphologic consequences of CsA therapy
have been limited by the lack of kidney biopsies before the
institution of CsA, by relatively short duration of CsA therapy, or
by the absence of appropriate controls. Several studies have been
performed in renal transplant recipients, where it is often impos-
sible to discriminate structural changes consequent to CsA ther-
apy from those of chronic rejection [8, 91. Also, in some diseases
treated with CsA, such as uveitis and psoriasis [10—13], the kidney
may be involved, and, again, the lesions of CsA and those of the
underlying disease may be present together and may be insepa-
rable. In addition, most studies performed in such patients lacked
baseline kidney biopsies, making the understanding of CsA's
contribution to the nephropathology difficult to ascertain. Re-
cently, however, Young Ct al [14] reported progressive tubuloin-
terstitial changes in renal biopsy specimens obtained at one and
three years after institution of CsA therapy for severe psoriasis,
but found no such changes in untreated psoriasis patients or
normal controls.
The present study quantitated renal structural changes consis-
tent with known morphologic consequences of CsA in a group of
PT recipients with IDDM. The study compared these PT patients
to a group of IDDM patients (comparison group) who did not
receive PT or who had a PT which failed early. Both groups had
renal biopsies performed at baseline and five years later.
Methods
Patients
The clinical and demographic features of these patients were
reported in a study of the effects of PT on diabetic glomerular
lesions [2]. Briefly, all patients spent one week in the Clinical
Research Center (CRC) at the University of Minnesota for
pre-pancreas transplant evaluation, during which they underwent
multiple 24-hour urine collections (at least 3) for measurements
of creatinine clearance and urinary albumin excretion rate (AER).
Blood pressure (BP) was measured repeatedly by the CRC
nursing staff. All the patients underwent percutaneous kidney
biopsy. Hb Al was used to assess glycemic control.
Pancreas transplant group
Thirteen IDDM patients [6 males, 7 females; age 32 7 (X
SD) years; duration of IDDM, 20 5 years] were studied before
489
490 Fioretto et a!: GsA nephrotoxicily in pancreas transplant recipients
and five years after successful PT. After the initial evaluation, the
patients underwent segmental or whole organ PT [1]. After
induction therapy all patients received triple immunosuppression
with prednisone, azathioprine and cyclosporine (CsA) [1]. One
patient was on CsA only for the first year following PT; all others
were on CsA for the five years of the study. Insulin was discon-
tinued after PT in all 13 patients. Measures of renal function and
metabolic parameters were restudied in most patients at 1, 2, 3.5
and 5 years after PT. A renal biopsy was performed in each
patient 2.0 0.4 and 5.0 0.3 years after PT. Two of the PT
recipients with advanced diabetic nephropathy and severe glomer-
ular and interstitial lesions at baseline underwent kidney trans-
plantation 7.7 and 6.3 years, respectively, after PT.
Comparison group
Ten IDDM patients (1 male, 9 females; age 28 10 years;
duration of IDDM, 16 7 years) had renal function studies and
kidney biopsy as part of their evaluation for PT. Three received a
pancreatic graft that failed within six weeks. The other seven
patients either decided against the PT procedure, could not obtain
insurance coverage for PT, or had multiple preformed HLA
antibodies and a matched graft did not become available. These
patients, still diabetic and receiving insulin therapy, volunteered
to have renal function studies and kidney biopsies repeated 5.4
1.4 years after the first evaluation. The comparison and the PT
patients were similar for age, duration of IDDM, glycemic control,
creatinine clearance, mean blood pressure, and AER at baseline
[2].
Procedures
These studies were approved by the Committee for the Use of
Human Subjects in Research of the University of Minnesota; all
patients gave written informed consent before each study. HbA1
was measured by BioRad column assay until November 1986 and
by HPLC thereafter (BioRad Diamat, Biorad Laboratories, Her-
cules, CA, USA). In some of the patients studied in the early
1980s, only total glycosylated hemoglobin was initially measured;
therefore in all patients, the values are expressed as total HbA1.
Creatinine clearances (Car) were measured on urine collections
done under careful supervision in our Clinical Research Center.
Serum and urine creatinine levels were measured by an auto-
mated kinetic method that uses the Jaffe reaction. AER was
measured by nephelometry using the Beckman kit (Beckman
Instruments, Inc., Fullerton, CA, USA). CsA blood levels were
measured by HPLC [15] on blood samples drawn 12 hours after
CsA administration.
Renal tissue was obtained by percutaneous biopsy and pro-
cessed for light and electron microscopy (EM) [16]. Morphomet-
nc measurements were performed by a single observer (PF),
except for measurements of tubular atrophy and arteriolar hyali-
nosis (MJM and EHS). Both these observers were unaware of the
patients' treatment and identity for these measurements. EM was
performed for estimation of glomerular basement membrane
(GBM) width and mesangial volume fraction [Vv(mes/glom)]; the
results of these EM studies have been previously reported [2].
Tissue for light microscopy was embedded in paraffin, cut in 2
to 3 im sections and stained with periodic acid-Shiff stain (PAS).
The fractional volume of the renal cortex which is interstitium
[Vv(Int/Cortex)] was estimated using a projecting microscope at
300X [17]. All available cortical tissue was measured. Points
falling on the interstitium, defined as the space outside Bowman's
capsule, tubular basement membrane and vessels larger than one
tubular diameter, and total number of points overlying the cortical
tissue were counted to estimate the Vv(Int/Cortex), using a 1:4
grid with a distance between fine points of 13 mm. The normal
values for Vv(Int/cortex) of 0.15 0.02 were determined from
biopsies of renal transplant donors [17]. The index of interstitial
fibrosis was determined by two observers (MM and PF) without
knowledge as to patient identity, with semiquantitative scores
applied as follows: 0 = normal; 1 + = early detectable areas of
interstitial fibrosis; 2+ = interstitial fibrosis involving 25 to 50%
of interstitial areas; 3 + = interstitial fibrosis involving >50% of
interstitial areas [18].
Percent sclerosed glomeruli was determined, as previously
described, only when at least 20 glomeruli were available for study
[19]. The normal value for percent sclerosed glomeruli is <10%
and was derived from biopsies of renal transplant donors [19].
The arteriolar hyalinosis score was obtained by grading as 0
normal arterioles, as 1.0 vessels with <50% of the arteriolar wall
replaced by hyaline material and as 2.0 vessels with >50% of the
arteriolar wall replaced by hyaline material. The sum of these
scores was then divided by the number of the arterioles evaluated.
(1 Xn<50%)+(2Xn>50%)
Arteriolar hyalinosis score =
totalnumber of artenoles
where n is the number of arterioles.
The index of tubular atrophy is a semiquantitative score going
from 0 to 4+: 0 is normal; 1 corresponds to minimal, which means
the presence of tubular atrophy in about 1 to 5% of tubules; 2 =
slight, corresponding to 5 to 15%; 3 = medium 15 to 30%; and 4
= severe more than 30% [20].
The presence of CsA arteriolopathy was blindly evaluated (by
MJM) as previously described [7].
Cyclosporine dose and blood levels
Figure 1 illustrates the changes in mean CsA daily dose and
CsA blood levels during the study. Each point in the figure
represents the mean value for the corresponding month. At each
time a highly significant correlation was observed between CsA
daily dose and CsA blood levels (P < 0.01 at each time). CsA dose
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Fig. 1. CsA mean daily dose (mg/kg/day) J) and GsA mean blood levels
(pg/liter) (U) at 1, 6, 12, 36, 48, and 60 months after PT. The values
represent the means (and 1 SD) of the values for that month. In this and

























GsA blood levels (12th month), jig/liter
300
Fig. 3. Con-elation between CsA blood levels during the 12th month post-PT
and the magnitude of decline in creatinine clearance (Ce) from baseline to




Fig. 2. Creatinine clearance (C) in recipients of PT at baseline and at 1, Z
3.5, and 5 years follow-up. Creatinine clearance fell from 102 21
ml/min/1.73 m2 to 68 24 (P < 0.0001) at five years after PT. The shaded
area represents the normal range. In this and subsequent figures, the open
symbols refer to the two patients who subseqnently required kidney
transplantation; D refers to the patient who was on GsA for only one year.
PT to 4.7 1.6 (3.9) mg/kg/day at five years after PT. CsA blood
levels decreased from 305 115 (317) to 94 38 (87) jig/liter.
For statistical analyses cumulative CsA doses and blood levels
at different times after PT were used. Thus, the mean daily CsA
dose and blood levels, respectively, during the first month (9.9
2.6 mg/kg/day, 305 115 jig/liter), the first three months (10.1
2.4, 265 98), the first six months (9.4 2.7, 227 84), the first
12 months (8.2 2.7, 190 62) after PT, and during the five years
of the study (6.1 1.8, 126 33) were used.
Statistics
AER values, since not normally distributed, are expressed as
median (range) and were logarithmically transformed before
analysis. Results are expressed as X 5D (median). Comparisons
of baseline with follow up data used the t-test for paired data,
while those between the two groups of patients employed the
f-test for unpaired data. Simple regression analysis was used to
evaluate the relationships between CsA dose and plasma levels at
different times and functional and structural changes over time.
Statistical significance was set at the level of P < 0.05. For clarity
of presentation all P values <0.10 are provided.
Since several parameters were expected to co-correlate, multi-
ple regression models were fit to the data using a stepwise model
selection procedure, to determine which parameter correlated
more strongly with the dependent variable. The level of signifi-
cance for a variable to enter the model was set at 0.15.
The following independent variables were considered in each of
the analyses: baseline Cc,., change in Cc,. at one year after PT
(except when this was the dependent variable), baseline Vv(Int/
Cortex), CsA doses and levels at different times (average first
month, first 3 months, first 6 months, first 12 months after PT and
during the 5 years of the study). Four models with four different
dependent variables were considered: (1) change in GFR at one
year, (2) change in Vv(Int/Cortex) at five years, (3) change in %
selerosed glomeruli at five years, and (4) change in tubular
athrophy score at five years.
Results
Clinical parameters
HbA1 became normal in all the PT patients (from 10.5 1.4 at
baseline to 6.6 0.7% at five years, P < 0.0001), with no changes
in the comparison group (from 11.3 1.9 to 11.8 2.2%).
Creatinine clearance (Ccr) decreased at five years in the trans-
planted patients (P < 0.0001, Fig. 2) and did not change signifi-
cantly in the comparison group (102 21 at baseline and 91 26
ml/min/1.73 m2 at five years, NS). The decline in Ccr was
significant in the first year in the PT patients but did not change
thereafter (Fig. 2). The magnitude of the decline in Ccr from
baseline to one year in the PT patients correlated with the mean
daily CsA dose during the twelfth post-PT month (r = 0.79, P <
0.002), as well as CsA blood levels during this month (r = 0.75, P
<0.004; Fig. 3). Similarly, the % decline from baseline in Cc,. in
the first year correlated with both twelfth month mean CsA dose
(r = 0.62, P < 0.03) and blood levels (r = 0.75, P < 0.004). By
stepwise multiple regression analyses (model 1), CsA dose during
the first year (P < 0.04) and CsA dose during the first six months
(P c 0.03) were significant in determining the change in Ccr at
one year. Serum creatinine increased after PT from 0.95 0.28 at
baseline to 1.38 0.61 mg/dl at five years (P < 0.004), but did not
change in the comparison group (baseline 0.88 0.14 and
follow-up 0.88 0.18 mg/dl). AER was not significantly different
after PT [120 (7—2900) at baseline and 40 (2—2860) mg/24 hr at 5
0 75 150 225
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years, NSJ, and tended to increase in the comprison group [12
(2—280) at baseline and 19 (5—2462) mg/24 hr at 5 years, P < 0.06].
Mean BP also did not change in either group (91 8 at baseline
and 92 10 mm Hg at 5 years in PT group; 85 6 at baseline and
85 7 mm Hg at 5 years in the comparison group). However, the
number of patients treated for hypertension increased from 2 to
11 in the PT group, and from 1 to 4 in the comparison group.
Morphometric findings
The glomerular morphometric data have been previously re-
ported [2]. Vv(Int/Cortex) increased after PT, but remained
essentially unchanged in the comparison group (Fig. 4). No
increase in Vv(Int/Cortex) was measured in the two year biopsies
(0.27 0.04 at two years vs. 0.26 0.05 at baseline). Also there
was no significant increase in interstitial fibrosis scores between
the baseline (0.82 0.91) and two year biopsies (1.11 0.87).
However, four PT patients had a more than 25% increase in
Vv(Int/Cortex) and four a more than 0.5 grade increase in the
interstitial fibrosis scores over this time. Increased Vv(Int/Cortex)
was evident five years after PT (0.33 0.08, P < 0.004 vs. baseline,
P < 0.04 vs. 2 year follow-up). The interstitial fibrosis score
increased significantly at five years (2.14 1.18, P < 0.003 vs.
baseline, P < 0.004 vs. 2 years). Vv(Int/Cortex) and the interstitial
fibrosis score were highly significantly correlated (r = 0.90, P <
0.0001). There was no change in Vv(Int/Cortex) in five years in the
comparison patients (0.25 0.03 vs. 0.25 0.03; Fig. 4).
Similarly, the index of tubular atrophy increased in five years in
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Fig. 4. Interstitial fractional volume in the PT recipients and in the compar-
ison patients at baseline (base) and follow-up (five years). The dashed line
represents the upper limit of normal in our laboratory (0.19). The asterisk
indicates that interstitial fractional volume increased significantly follow-
ing PT (P < 0.005); it was unchanged in the comparison patients.
Base 5 years Base 5 years










Pancreas transplant IDDM comparison
recipients patients
Fig. 5. Sclerosed glomeruli (%) in the PT recipients and in the comparison
patients at baseline (base) and follow-up (five years). The dashed area
represents the normal range in our laboratory (<10%). The asterisk
indicates that the percent of globally sclerosed glomeruli increased
significantly following PT (P < 0.005); it was unchanged in the comparison
patients.
did not change significantly in the comparison group (11.1 7.1
vs. 7.5 6.6 at baseline, P < 0.09). The increase in tubular
atrophy tended to correlate with the increase in Vv(Int/Cortex)
over five years but this did not reach statistical signifIcance (r =
0.6, P < 0.07).
Percent sclerosed glomeruli was 12.7 17.1% at baseline, 16.2
12.6% at two years (NS), and 39.8 27.8% at five years
post-PT (P < 0.002 vs. baseline and P < 0.004 vs. 2 years; Fig. 5).
No significant change in percent sclerosed glomeruli was observed
over five years in the controls (13.2 18.8% vs. 6.2 8.2% at
baseline, NS).
Arteriolar hyalinosis scores were stable over the five years of
the study in the PT patients (0.35 0.25 vs. 0.37 0.14 at
baseline, NS), but increased in the comparison patients (0.56
0.20 at five years vs. 0.36 0.11 at baseline, P < 0.03).
CsA-associated arteriolopathy lesions were rare (<5% of all
arterioles present in the bipsies) and were difficult to differentiate
from diabetic arteriolar lesions. Although CsA-associated arte-
riolopathy lesions appeared to be mainly found in pancreas
transplant patients receiving CsA, indistinguishable lesions were
present in some baseline biopsies or in follow-up biopsies of
comparison patients who had not received CsA. Thus these data
were not statistically analyzed.
The increase from baseline in Vv(IntlCortex) over five years in
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CSA blood levels (1st year), p.9/liter
Fig. 6. Correlation between GSA blood levels during the first year post-PT
(pg/liter) and changes in Vv(interstitium/cortex) from baseline to five years
afterPT(r 0,62, P <0.03).
the PT patients correlated with both the mean daily CsA dose in
the first month (r = 0.6, P < 0.05), and with the mean daily CsA
dose in the first post-transplant year (r = 0.62, P < 0.04). As well,
the mean of CsA blood levels in the first year correlated directly
with the increase from baseline in Vv(Int/Cortex) over five years
in the PT patients (r = 0.68, P < 0.03; Fig. 6). Similar correlations
were observed when the increase in interstitium in five years was
expressed as % over baseline.
The strongest predictor of the increase in Vv(Int/Cortex) over
five years was the decline in GFR in the first year (r = 0.76, P <
0.005); similarly the % decline in GFR in the first year correlated
with the % increase in Vv(Int/Cortex) (r =0.8,P < 0.003; Fig. 7).
By stepwise multiple regression analysis, change in Crat one
year (P < 0.03) and CsA blood levels in the first three months
(P < 0.03) were significant in determining the change in Vv(Int/
Cortex) at five years. None of the variables was significant when
change in % scierosed glomeruli at five years or change in tubular
atrophy at five years were considered as the dependent parame-
ters.
Discussion
This study demonstrates that renal lesions known to be associ-
ated with long-term CsA administration develop in the native
kidneys of IDDM PT recipients. The severity of these lesions in
the PT recipients after five years of CsA therapy was strongly
predicted by CsA blood levels, CsA dose, and magnitude of the
decline in Ce,. during the first post-transplant year. Additionally,
this study showed that the adverse effects of CsA on renal
structure could be missed if examined after only two years of CsA
therapy. The study design was important in allowing us to make
these observations: in this study Cr and renal biopsies were
performed before the administration of CSA and two and five
years later, as determined by protocol, not by clinical events. This








Fig. 7. Correlation between the magnitude of decline in creatinine clearance
(Cc,) during the first year post-PT (expressed as % change over baseline
values) and changes in Vv(interstitium/cortex) from baseline to five years after
PT (r = 0.80, P < 0.003).
all the patients on CSA therapy were studied for the prolonged
duration of five years. An additional advantage of the study's
design was the availability of GFR and kidney biopsies, performed
five years apart, in a comparison group, with the same underlying
systemic disease (IDDM).
Recently we reported, in the same patients as presented here,
that five years of euglycemia resulting from successful pancreas
transplantation were unable to reverse established diabetic gb-
merular structural changes in long-term IDDM patients [2].
The finding of increased interstitial fibrosis, tubular atrophy,
and global glomerular sclerosis in CsA-treated PT recipients, as
opposed to the stability of these lesions over five years in the
comparison patients, indicates that these lesions are consequences
of CsA administration, and not of the preexisting diabetic state in
PT recipients. This view is strongly supported by the observations
that the severity of interstitial expansion over five years and CsA
blood levels and dosages were highly significantly correlated.
Renal morphological changes induced by CsA have been
extensively described [4—10]. CsA nephrotoxicity is said to be
characterized by tubulointerstitial lesions of focal (striped) inter-
stitial fibrosis associated with tubular atrophy within the areas of
fibrosis. Arteriolar alterations including ring or nodular hyalino-
sis, intimal fibrosis and mucoid thickening of the intima have also
been described [7].
Glomerular changes have not often been reported. However,
focal segmental glomerulosclerosis has been described in renal
allografts in conjunction with CsA-associated arteriolopathy [22].
Also, increased numbers of obsolescent glomeruli have been seen
in cases of advanced interstitial fibrosis and tubular atrophy in the
native kidneys of CsA patients [5, 7, 10].
In this study we concentrated on the interstitial, tubular, and
gbomerubosclerotic lesions since diabetic- and CsA-associated
arteriobopathy may, as confirmed here, be impossible to differen-
tiate structurally [7]. Also, CsA-associated arteriolar lesions can
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regress upon CsA dose reduction [23], and our first biopsies after
PT in CsA-treated patients were performed only after two years,
one year after the major CsA dose reductions were made.
Arteriolar hyalinosis lesions increased in IDDM control patients,
but remained stable after PT. It is possible that PT prevented
progression of these diabetic lesions, or even ameliorated them,
and that arteriolar hyalinosis changes due to CsA were not
pronounced enough to outweigh this beneficial effect.
The average increase in Vv(Int/Cortex) of 23% and the increase
in the frequency of sclerotic glomeruli from 13 17% to 40
28% in the PT represents a serious deterioration in renal structure
which, if progressive, could foretell irreversible renal functional
deterioration. As mentioned, we found direct correlations be-
tween the five year increase in the interstitial space, measured as
Vv(Int/Cortex), and measures of CsA blood levels and doses
during the first post-PT year but not thereafter. The majority of
the PT patients were treated with CsA doses which have been
considered to be "high" (>5 mg/kg/day) [24]. Therefore, we could
not separately analyze patients on "low" and "high" CsA dose (<
and >5 mg/kg/day) as has been done in previous studies [24].
Nonetheless, our linear regression analyses did not indicate a
threshold effect for CsA-induced renal injury at mean doses
between 3 and 12 mg/kg/day during the first year. Rather, there
was a progressive worsening in measures of interstitial expansion
with increasing CsA dose.
The best predictor of the five-year increase in Vv(Int/Cortex)
was the degree of decline in Cr after one year of CsA therapy. It
is possible that the decline in Ce,. at shorter times after the
institution of CsA therapy could be a better predictor; however,
our patients were regularly evaluated by protocol only after one
year following PT. The decline in C at one year post-PT was
closely related to the CsA dose and blood levels at the same time
(mean of 12th month dose and level values). Thus, it is not
surprising that average CsA blood levels and dose during the first
year were also strongly predictive of the increase in interstitial
fibrosis over five years. Tomlanovich et al have reported that Ccr
systematically underestimates the decline in glomerular filtration
rate (GFR) as measured by inulin clearance, particularly if the
inulin GFR is less than 60 ml/min/1.73 m2 [25]. This observation
would serve to strengthen the findings of the current study which
used Cr to estimate GFR.
Several studies have investigated the relationships between
CSA dose and/or blood levels and changes in renal function and
structure [23, 26—28]. These studies, however, lacked baseline
biopsies for evaluating changes in lesions over time and often
lacked a control group with the same underlying disease. Thus,
when kidney biopsies were analyzed in patients with psoriasis
either untreated with CsA or treated with low dose CsA for a
mean of 15 months, similar minimal or slight interstitial and
vascular changes were observed in both groups [13]. These results
emphasize the importance of baseline or control biopsies. Also, in
these studies the range of duration of CsA therapy was very wide
and the follow-up of the patients was much shorter than in our
study. A correlation between CsA dose (but not blood levels) and
CsA-induced renal lesions has been described by Feutren and
Mihatsch [24] and Svenson, Bohman and Hallgren [26], but not by
others [14, 23, 27, 28]. In the present study CsA blood levels in the
first year were even stronger predictors than CsA dose for changes
in interstitium five years after PT. This makes sense considering
patient variability in absorption and turnover of CsA as well as
possible variability in compliance. Also, associations of blood
levels and outcomes such as changes in renal function and
structure may be easier to observe when blood levels are obtained
at fixed times after CsA dosing and are measured in a single
laboratory. As well, these relationships of CsA dose and level to
decline in GFR and to severity of lesions, may be more apparent
when there is more variation in CsA dose among the patients.
This may explain why, despite baseline observations and appro-
priate controls, these relationships were not detected in CsA-
treated psoriasis patients [14].
We did not find progression of interstitial expansion in the two
year biopsies as compared to baseline biopsies in PT patients;
these findings contrast with the majority of earlier reports describ-
ing CsA-induced lesions after short-term treatment [9, 10, 14, 24,
29, 30]. For example, Zachariae et al [30] compared kidney
biopsies performed before and after one year of low-dose CsA
therapy in psoriatic patients, and found a slight but significant
increase in interstitial expansion. Similarly, in a well-designed
study with appropriate controls, Young et al described tubuloin-
terstitial lesions in psoriasis patients after one year of CsA
therapy, and these lesions progressed over the subsequent two
years of CsA treatment [14]. We do not have a clear understand-
ing of these discrepant results. One possibility is that underlying
diabetic interstitial lesions of variable severity may have made
subtle CsA changes at two years more difficult to detect than in
the above studies, where kidney structure was closer to normal at
baseline [14, 30]. Another possibility is that normoglycemia
following PT induced a relative decrease in the volume of the
interstitial compartment, offsetting any early increase caused by
CsA. A third possibility is that of methodologic differences in the
measurement of the lesions. However, whether we did not find
changes at two years because they were not present or because
they were not measurable, one of the main conclusions of the
present study is that there was progression of CsA related lesions
between the second and the fifth year of treatment, despite
reduced CsA dose and levels during these later years. Along these
lines, Habib and Niaudet [31] also reported that some children on
long-term CsA therapy for idiopathic nephrosis had little or no
CsA-related renal lesions on initial (average 13 months) post-
treatment biopsy, but showed important lesions in subsequent
(average 29 months) biopsies.
The value of early changes in serum creatinine or Cr in
predicting early CsA renal structural changes has been previously
described [24, 26, 30]. However, this is the first study addressing
whether early renal functional changes predict late CsA structural
changes. The present study demonstrates that a change in Cr at
one year is a strong predictor of the development of late intersti-
tial lesions. Thereafter tubulointerstitial lesions progress, despite
stable Ce,. [32]. Thus stable Cr in CsA-treated patients cannot be
interpreted as indicating a lack of progressive renal injury.
Our studies also describe progression of the lesion of global
glomeruloscierosis over five years in the PT recipients. Similar
findings have been described in CsA-treated heart transplant [5]
and uveitis [10] patients. These are important renal structural
changes which may independently contribute to ultimate deteri-
oration in renal function. The increase in global glomerulosclero-
sis may not have been noted in many short-term studies because
it appears to require a longer time to become evident.
In summary, these studies document the development of fin-
portant interstitial, tubular, and glomerular lesions in the native
kidneys of PT patients treated with CsA. The interstitial lesions
were closely related to early CsA blood levels and effects of CsA
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on depression of GFR. PT does not result in amelioration of
specific lesions of diabetic glomerulopathy in five years [2], but is
associated with marked worsening of overall renal structure based
upon these CsA-induced changes. Thus, so long as nephrotoxic
drugs remain a component of the immunosuppressive protocols,
PT may negatively impact on the kidney. PT in patients with
native kidneys should, therefore, only be considered for debilitat-
ing or lifethreatening metabolic instability [33]. Similar "cost-
benefit" analyses applied to other relative indications for long-
term CsA therapy such as psoriasis, uveitis, and rheumatoid
arthritis, would suggest that only the most severe cases should be
selected for long-term CsA treatment.
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